The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...

The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.

A delay in getting to the rapid eye movement (REM) stage of sleep may be linked to Alzheimer's disease and related dementias, ...

However, some research suggests that poor sleep could raise your risk of Alzheimer’s. A study published in November found ...

A pathway once considered fundamental in Alzheimer’s disease is being studied intensely again, and may soon result in safer, ...

Delays in dreaming might be an early warning sign of Alzheimer's disease. People who take significantly longer to enter the ...

Taking too long to enter the phase of sleep in which we dream may be an early sign of Alzheimer's disease. This is the ...

The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's ...

One recent analysis found that, over the course of three years, people taking semaglutide (the compound in Ozempic and the weight loss drug Wegovy) were about 40 to 70 percent less likely to be ...

Funded by a $3 million National Institutes of Health grant, the two universities plan to study the relationship between two ...

European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for ...

New research uncovers how declining protein clearance mechanisms with age lead to Alzheimer’s, Parkinson’s, and other ...